Tandem Diabetes Care, Inc. (TNDM) Rating Reiterated by Robert W. Baird

Robert W. Baird reaffirmed their hold rating on shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in a research report released on Sunday morning. The brokerage currently has a $3.00 target price on the medical device company’s stock.

A number of other brokerages have also weighed in on TNDM. Piper Jaffray Companies restated a hold rating and set a $15.00 target price on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a hold rating to a buy rating and set a $7.50 target price for the company in a research report on Thursday, September 28th. Finally, Wedbush restated an outperform rating and set a $17.00 target price (down previously from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $11.29.

Shares of Tandem Diabetes Care (TNDM) opened at $2.66 on Friday. The company has a debt-to-equity ratio of -2.70, a quick ratio of 0.88 and a current ratio of 1.90. Tandem Diabetes Care has a 52 week low of $2.15 and a 52 week high of $30.00.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, October 26th. The medical device company reported ($3.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($3.74) by $0.65. The firm had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.92 million. Tandem Diabetes Care had a negative net margin of 79.45% and a negative return on equity of 1,177.11%. The company’s revenue for the quarter was up 119.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.97) earnings per share. analysts forecast that Tandem Diabetes Care will post -15.18 EPS for the current fiscal year.

WARNING: This story was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://transcriptdaily.com/2017/11/23/tandem-diabetes-care-inc-tndm-rating-reiterated-by-robert-w-baird.html.

In related news, CEO Kim D. Blickenstaff bought 285,700 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The stock was purchased at an average price of $3.50 per share, for a total transaction of $999,950.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 20.90% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of TNDM. Bank of America Corp DE boosted its position in shares of Tandem Diabetes Care by 88.6% during the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after acquiring an additional 404,452 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Tandem Diabetes Care by 93.3% during the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock valued at $465,000 after purchasing an additional 280,551 shares during the last quarter. Wedbush Securities Inc. lifted its position in Tandem Diabetes Care by 88.6% during the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock valued at $138,000 after purchasing an additional 88,709 shares during the last quarter. Keybank National Association OH lifted its position in Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after purchasing an additional 72,177 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after purchasing an additional 32,991 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply